1234365-97-9

Tenapanor (AZD1722) HCl is a potent, orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor HCl reduces intestinal phosphate absorption predominantly through the reduction of passive paracellular phosphate flux. Tenapanor HCl has the potential to be used in research on hyperphosphatemia.

Tenapanor hydrochloride is a minimally absorbed small molecule sodium/hydrogen exchange isomer 3 (NHE3) inhibitor. NHE3 is involved in the uptake of sodium ions and water into the intestinal lumen, and by inhibiting NHE3, tenapanor is expected to reduce sodium absorption and increase fecal sodium and fluid excretion.

Tenapanor hydrochloride is generally well tolerated, with diarrhea being the most common adverse reaction. Diarrhea is usually transient (lasting 1 week) and mild to moderate in severity. Diarrhea develops within a week of starting treatment in approximately half of cases and within the first 3 weeks of treatment in two-thirds of cases. Other possible side effects include abdominal pain, nausea, bloating, and flatulence^[1].

Synthesis of Tenapanor hydrochloride

[1] WILLIAM D CHEY. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).[J]. American Journal of Gastroenterology, 2021, 116 6: 1294-1303. DOI:10.14309/ajg.0000000000001056.